17 January 2003 23:43 [Source: ICIS news]
HOUSTON (CNI)--Moody's Investors Service Friday downgraded Schering-Plough's (S-P) long-term credit rating due in part to the drop in Claritin revenues after the drug was switched to the over-the-counter market from prescription sales.
The corporate credit watchdog also cited two other reasons for the S-P downgrade from Aa2 to A1 - uncertain prospects for Clarinex in the prescription antihistamine market and potential competition for the Intron-A franchise and for Remicade.
Moody's said all three factors put Schering-Plough at a heightened operating risk, saying they would result in a weaker and more variable cash flow from operations and that free cash flow could therefore be negative in future years.
Other reasons for the downgrade, Moody's said, were the company's lagging share price and upcoming changes in senior leadership.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|